DSE:IBNSINA
The IBN SINA Pharmaceutical Industry PLC research
Reports on The IBN SINA Pharmaceutical Industry PLC
Peer comparisons and industry research covering The IBN SINA Pharmaceutical Industry PLC
Company · DSE:ORIONINFU · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Orion Infusion: FY2025 sales fell 20% to BDT 665m and 9M FY2026 sales fell a further 3.5%, while the shares trade at 131x trailing earnings
Bangladesh's largest dedicated IV-fluid maker has not grown in ten years: revenue was BDT 730m in FY2016 and BDT 665m in FY2025. ROE has stayed at 11-16%, a BDT 306m bank line costs 12.9%, and capacity use fell to 75%. A BDT 205m line expansion, to be funded internally, is due to finish in December 2026.
Orion Infusion Limited (OIL) makes intravenous (IV) fluids and other injectable "parenteral" products at a single plant and sells them to hospitals, clinics and pharmacies across Bangladesh. It is a member of the Orion Group, listed on the Dhaka Stock Exchange in 1994, and has…
Company · DSE:NAVANAPHAR · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026
Navana Pharmaceuticals: sales up 28% and factories at 98% of capacity, but interest takes half of operating profit
FY2025 net sales rose 28.2% to BDT 8.84bn and operating profit 45.4%, yet finance expenses of BDT 750m left a 5.5% net margin. Borrowings fell from BDT 5.27bn to BDT 3.78bn by March 2026; FY2026 EPS was BDT 5.93.
Navana Pharmaceuticals PLC makes and sells generic medicines for people and animals in Bangladesh, and exports a small part of its output. Its fiscal year runs from 1 July to 30 June; FY2025 is the year to 30-Jun-2025. The company was incorporated in 1986, merged…